Drinkwater D C, Cushen C K, Laks H, Buckberg G D
Department of Cardiothoracic Surgery, University of California, Los Angeles.
J Thorac Cardiovasc Surg. 1992 Nov;104(5):1349-55.
The benefits of combined antegrade-retrograde infusion of blood cardioplegic solution are becoming well known in adult coronary and valvular heart operations. Many of these advantages relate directly to the pediatric patient. They include prompt arrest and even distribution, particularly with aortic insufficiency or open aortic root, avoiding or limiting ostial cannulation, allowing uninterrupted surgical procedures, and flushing air/debris from the coronary arteries. We therefore report on the first 123 pediatric patients at the University of California, Los Angeles, to receive myocardial protection with antegrade (aortic) infusion in conjunction with retrograde (coronary sinus) infusion of blood cardioplegic solution. We employed a retroplegia catheter with a self-inflating and deflating occlusion balloon on the tip of a pressure-monitored infusion cannula that remains in the coronary sinus during the operation. Induction blood cardioplegic solution, 30 ml/kg in equally divided doses, is administered in the coronary sinus first antegrade at an aortic pressure less than 80 mm Hg, followed by retrograde infusion at less than 40 mm Hg. Maintenance cardioplegic solution (15 ml/kg) is administered every 20 minutes through one or both of the infusion cannulas, depending on the surgical procedure. Patients' ages ranged from 1 week to 16 years with a mean of 4.6 years. The following procedures were included in descending order: Fontan 20, atrioventricular valve repair/replacement (and complete atrioventricular canal) 16, aortic root/Konno/Ross 16, Rastelli 13, aortic valve repair/replacement 13, ventricular septal defect (and double-outlet right ventricle) 13, tetralogy of Fallot 10, coronary artery reimplantation/fistula repair 6, truncus arteriosus 4, arterial switch 3, bidirectional Glenn 2, sinus venosus 2, and aortopulmonary window, Senning, Stansel, interrupted aortic arch, and Ebstein's, 1 each. Aortic crossclamp times ranged from 6 to 219 minutes with a mean of 87 minutes. Myocardial oxygen consumption data for a series of six patients indicated the supplemental benefit for retrograde infusion of cardioplegic solution along with antegrade infusion, particularly in hypertrophied myocardium. Three deaths occurred (2.4% 30-day mortality), in the following patients: the first with truncus arteriosus and interrupted aortic arch, the second with complete atrioventricular canal and pulmonary hypertension, and the third with truncal valve regurgitation and replacement. There were no complications related to the retroplegia catheter. From this initial positive experience, we conclude that (1) combined antegrade-retrograde infusion of blood cardioplegic solution can be safely used in an expanding number of pediatric heart operations in all age groups, and (2) combined antegrade-retrograde infusion of blood cardioplegic solution may provide additional myocardial protection, with excellent surgical outcome, in complex congenital heart repairs.
在成人冠状动脉和心脏瓣膜手术中,顺行 - 逆行联合灌注血液心脏停搏液的益处已广为人知。其中许多优点直接适用于儿科患者。这些优点包括迅速停搏和均匀分布,特别是在主动脉瓣关闭不全或主动脉根部开放的情况下,避免或限制开口插管,允许手术过程不间断进行,以及从冠状动脉冲洗空气/碎屑。因此,我们报告了加利福尼亚大学洛杉矶分校首批123例接受顺行(主动脉)灌注联合逆行(冠状窦)灌注血液心脏停搏液进行心肌保护的儿科患者。我们使用了一种逆行停搏导管,其在压力监测灌注套管的尖端带有一个可自动充气和放气的阻塞球囊,在手术过程中该球囊留在冠状窦内。诱导性心脏停搏液,30 ml/kg,等分为剂量,首先在主动脉压力低于80 mmHg时经冠状窦顺行给药,然后在低于40 mmHg时逆行灌注。维持性心脏停搏液(15 ml/kg)每20分钟通过一个或两个灌注套管给药,具体取决于手术操作。患者年龄从1周龄至16岁不等,平均年龄为4.6岁。以下手术按降序排列:Fontan手术20例,房室瓣修复/置换(以及完全性房室通道)16例,主动脉根部/Konno/Ross手术16例,Rastelli手术13例,主动脉瓣修复/置换13例,室间隔缺损(以及右心室双出口)13例,法洛四联症10例,冠状动脉再植/瘘管修复6例,永存动脉干4例,动脉调转术3例,双向Glenn手术2例,静脉窦型2例,以及主肺动脉窗、Senning手术、Stansel手术、主动脉弓中断和Ebstein畸形各1例。主动脉阻断时间从6分钟至219分钟不等,平均为87分钟。一系列6例患者的心肌氧消耗数据表明,顺行灌注联合逆行灌注心脏停搏液具有额外的益处,特别是在肥厚心肌中。发生了3例死亡(30天死亡率为2.4%),具体患者如下:第一例患有永存动脉干和主动脉弓中断,第二例患有完全性房室通道和肺动脉高压,第三例患有永存动脉干瓣膜反流并进行了置换。未发生与逆行停搏导管相关的并发症。基于这一初步的积极经验,我们得出结论:(1)顺行 - 逆行联合灌注血液心脏停搏液可安全地用于越来越多的各年龄组儿科心脏手术中;(2)在复杂先天性心脏病修复手术中,顺行 - 逆行联合灌注血液心脏停搏液可能提供额外的心肌保护,并取得优异的手术效果。